IL2RA and lymphopenia: - TIL and immune signatures in on treatment biopsy associated with efficacy in Group A (Neoadjuvant)- All 18 patients developed anti-drug antibodies- Treatment induced transient lymphopenia on day 3 with subsequent rebound lymphocytosis- Increased levels of soluble IL-2Rα and CRP suggesting immune activation